Dose synthesis card for use with automated biomarker production system
View Patent ↗Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall.
1. A disposable microfluidic radiopharmaceutical synthesis card system comprising:
at least one reaction vessel adapted to receive a radioisotope and at least one reagent, said reaction vessel being configured to receive energy from an energy source in energy-transfer communication with an energy source, whereby when said radioisotope and said at least one reagent are mixed in said reaction vessel and energy is provided to said reaction vessel from said energy source, a radiopharmaceutical solution is synthesized;
at least one purification component to purify said radiopharmaceutical solution;
a filter adapted to sterilize said radiopharmaceutical solution;
a sterile syringe adapted to receive sterile radiopharmaceutical solution following the passage of said radiopharmaceutical solution through said purification column and said filter; and
a port in said syringe used to extract a sample of said radiopharmaceutical solution for quality control testing;
wherein said reaction vessel, said purification component, said port, and said filter are incorporated into a disposable card, said card being discardable after one (1) run.
2. The system of claim 1 further comprising a sample card adapted to receive multiple aliquots of said purified radiopharmaceutical solution for testing following said purified radiopharmaceutical solution's passage through said purification column.
3. The system of claim 1 wherein at least one of said at least one purification component is selected from the group consisting of trap and release, and solid phase extraction.
4. The system of claim 1 wherein at least one of said reagents is located on the card.
5. The system of claim 1 wherein said radioisotope is selected from the group consisting of carbon-11, nitrogen-13, oxygen-15, fluorine-18, iodine-124, and gallium-68.
6. The system of claim 1 wherein said radiopharmaceutical is selected from the group consisting of [18F]-2-fluoro-2-deoxy-D-glucose, [18F]Sodium Floride, [18F] 3′-deoxy-3′fluorothymidine, [18F]fluoromisonidazole, [18F]flurocholine, [18F]Fallypride, [18F]Florbetaben, [18F]Florbetapir, [18F]-fluoro-ethyl-tyrosine, [18F]flutemetamol, [18F]FDOPA, [11C]Choline, [11C]methionine, [11C]acetate, [11C]N-Methylspiperone, [11C]Carfentanil and [11C]Raclopride.
7. A disposable microfluidic radiopharmaceutical synthesis card comprising:
at least one reaction vessel adapted to receive a radioisotope and at least one reagent, said reaction vessel being in energy-transfer communication with an energy source, whereby when said radioisotope and said at least one reagent are mixed in said reaction vessel and energy is provided to said reaction vessel from said energy source, a radiopharmaceutical solution is synthesized;
at least one purification component used to purify said radiopharmaceutical solution;
a port used to extract a sample of said radiopharmaceutical solution for quality control testing;
a filter adapted to sterilize said radiopharmaceutical solution; and
a sterile syringe to receive sterile radiopharmaceutical solution following the passage of said radiopharmaceutical solution through said purification column and said filter.
8. The card of claim 7 wherein at least one of said at least one purification component is selected from the group consisting of trap and release, and solid phase extraction.
9. The card of claim 7 wherein at least one of said reagents is located on the card.
10. The card of claim 7 wherein said radioisotope is selected from the group consisting of carbon-11, nitrogen-13, oxygen-15, fluorine-18, iodine-124, and gallium-68.
11. The card of claim 7 wherein said radiopharmaceutical is selected from the group consisting of [18F]-2-fluoro-2-deoxy-D-glucose, [18F]Sodium Floride, [18F] 3′-deoxy-3′fluorothymidine, [18F]fluoromisonidazole, [18F]flurocholine, [18F]Fallypride, [18F]Florbetaben, [18F]Florbetapir, [18F]-fluoro-ethyl-tyrosine, [18F]flutemetamol, [18F]FDOPA, [11C]Choline, [11C]methionine, [11C]acetate, [11C]N-Methylspiperone, [11C]Carfentanil and [11C]Raclopride.